Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Single-cell transcriptome analysis of subclonal heterogeneity in primary glioblastomas
EF 2015-16
Résumé
Despite remarkable research efforts, brain tumours remain largely incurable diseases affecting both children and adults. Of these malignancies, glioblastomas (GBMs) occur most often and have the worst clinical outcomes. Current therapies minimally extend patient survival, with the majority of cases resulting in relapse. Recently, researchers have discovered brain tumours contain a small number of cells with stem cell properties. These brain tumour stem cells (BTSCs) have been shown to drive tumour growth and resistance to therapy. The uncontrolled behaviour of BTSCs originates from erroneous DNA packaging within cells – an unfortunate result of mutations in the DNA sequence. This project focuses on understanding the link between genetic alterations in BTSCs and the oncogenic mechanisms that promote tumour growth in GBM. The presence of numerous cancer cell populations within a single tumour is a confounding issue for GBM treatment. We will perform comprehensive genomic analysis of expressed genes in single cells isolated from primary GBM tumours to define the unique expression profile of BTSCs. We predict that BTSCs will have a gene expression signature distinct from other cell populations within the tumour. Identifying unique genomic aberrations and subsequent dysregulated pathways in BTSCs will help us understand the underlying cellular mechanisms responsible for therapeutic resistance in the overall tumour population. Nomination of functional pathways in tumour cells has the potential to translate into new drug targets and ultimately increased patient survival.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350035
Name
Richards Laura
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Single-cell transcriptome analysis of subclonal heterogeneity in primary glioblastomas
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumour Stem Cells; Cancer; Cancer Stem Cells; Clonal Heterogeneity; Epigenetic Pathways; Genomic Analysis; Glioblastoma; Single-Cell Rna Sequencing; Somatic Alterations; Transcriptome
Abstract
Despite remarkable research efforts, brain tumours remain largely incurable diseases affecting both children and adults. Of these malignancies, glioblastomas (GBMs) occur most often and have the worst clinical outcomes. Current therapies minimally extend patient survival, with the majority of cases resulting in relapse. Recently, researchers have discovered brain tumours contain a small number of cells with stem cell properties. These brain tumour stem cells (BTSCs) have been shown to drive tumour growth and resistance to therapy. The uncontrolled behaviour of BTSCs originates from erroneous DNA packaging within cells – an unfortunate result of mutations in the DNA sequence. This project focuses on understanding the link between genetic alterations in BTSCs and the oncogenic mechanisms that promote tumour growth in GBM. The presence of numerous cancer cell populations within a single tumour is a confounding issue for GBM treatment. We will perform comprehensive genomic analysis of expressed genes in single cells isolated from primary GBM tumours to define the unique expression profile of BTSCs. We predict that BTSCs will have a gene expression signature distinct from other cell populations within the tumour. Identifying unique genomic aberrations and subsequent dysregulated pathways in BTSCs will help us understand the underlying cellular mechanisms responsible for therapeutic resistance in the overall tumour population. Nomination of functional pathways in tumour cells has the potential to translate into new drug targets and ultimately increased patient survival.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Richards, Laura
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~